The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021268-13

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the research project is to determine the effect of twelve weeks’ treatment with an aromatase inhibitor (Femara®, 2.5mg weekly) on the change in the serum concentration of the pro-inflammatory cytokine, C Reactive Protein, as measured by the Roche® Cobas immuno-turbidimetric test and compare it to that of twelve weeks’ treatment with a depot intramuscular formulation of testosterone undecanoate (Nebido®, 1g every 6 weeks) and to that of six weeks of no treatment.


Critère d'inclusion

  • Obesity Related Male Hypogonadism